Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

19 May 2026 - 22 May 2026
17 Jun 2026 - 19 Jun 2026

"High Normal” Blood Pressure Linked to Significant Cardiovascular Risk

By HospiMedica staff writers
Posted on 10 Jun 2008
A new study has found that more than 70% of patients identified as having "high-normal” systolic blood pressure as measured through traditional cuff blood pressure measurement may be at serious cardiovascular risk. More...


Researchers at Cambridge University (UK) and Cardiff University (UK) conducted The Anglo Cardiff Collaborative Trial (ACCT), which tracked the blood pressure of 10,613 patients with two systems; a traditional blood pressure measurement using an inflatable arm cuff, and a non-invasive central blood pressure assessment using a device called the SphygmoCor. The investigators found that more than 70% of patients with brachial systolic blood pressure in the "high normal” range (130-139 mm Hg) had central systolic blood pressures corresponding to those seen in patients with stage one hypertension (140-159 mm Hg measured brachially). Elevated central pressure was also found to be associated with an increase in cardiovascular risk factors. The findings of the study further confirm the results of the Cardioblate Atrial Fibrillation (CAFÉ) and Strong Heart studies, both of which showed that individuals with elevated central pressure were at a significantly higher risk of cardiovascular events such as heart attack, stroke, and kidney disease. In both studies, elevated central pressure in patients could not be predicted by conventional brachial blood pressure measurement. The study was published in the June 2008 issue of the journal Hypertension.

"The real significance of these findings is that central and brachial blood pressures are not the same, meaning that central pressure cannot simply be inferred from the brachial pressure measurement, but should also be assessed,” said lead author Carmel McEniery, M.D. "Current guidelines for the diagnosis and management of hypertension are based solely on brachial pressure, yet this results in a large number of individuals being mis-classified based on their central pressure, leading to sub-optimal treatment.”

The SphygmoCor, a product of AtCor Medical (West Ryde, Australia), provides tools for non-invasive assessment of the cardiovascular system and autonomic function. SphygmoCor technology is centered on a transfer function that derives the pressure wave at the ascending aorta via a patented mathematical model of the properties of the brachial artery, and provides important central data through a non-invasive recording of the pressure wave at the radial artery. Current treatment guidelines call for anti-hypertensive drug therapy for stage one hypertension whereas life-style changes only are guided in the high normal range.


Related Links:
Cambridge University
Cardiff University
AtCor Medical

New
Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
Gold Member
12-Channel ECG
CM1200B
New
Vessel Sealing Instrument
ERGOseal
New
Tourniquet System
heidi– mein Tourniquet
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Copyright © 2000-2026 Globetech Media. All rights reserved.